231 related articles for article (PubMed ID: 29573392)
21. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
[TBL] [Abstract][Full Text] [Related]
22. 123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy.
Nicastro N; Garibotto V; Burkhard PR
Clin Nucl Med; 2018 Feb; 43(2):e33-e36. PubMed ID: 29215405
[TBL] [Abstract][Full Text] [Related]
23. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy.
Perju-Dumbrava LD; Kovacs GG; Pirker S; Jellinger K; Hoffmann M; Asenbaum S; Pirker W
Mov Disord; 2012 Jan; 27(1):65-71. PubMed ID: 22102521
[TBL] [Abstract][Full Text] [Related]
24. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
[TBL] [Abstract][Full Text] [Related]
25. [Functional assessment of nigro-striatal pathway with FP-CIT in patients with multiple system atrophy subtype C].
Martínez del Valle Torres MD; Ramos Moreno E; Amrani Raissouni T; Ortega Lozano SJ; Sanz Viedma S; Jiménez-Hoyuela JM
Med Clin (Barc); 2011 Oct; 137(10):440-3. PubMed ID: 21396668
[TBL] [Abstract][Full Text] [Related]
26. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.
Varrone A; Marek KL; Jennings D; Innis RB; Seibyl JP
Mov Disord; 2001 Nov; 16(6):1023-32. PubMed ID: 11748733
[TBL] [Abstract][Full Text] [Related]
27. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography.
Gilman S; Koeppe RA; Junck L; Little R; Kluin KJ; Heumann M; Martorello S; Johanns J
Ann Neurol; 1999 Jun; 45(6):769-77. PubMed ID: 10360769
[TBL] [Abstract][Full Text] [Related]
28. Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations.
Ko JH; Lee CS; Eidelberg D
J Cereb Blood Flow Metab; 2017 Feb; 37(2):683-693. PubMed ID: 26980757
[TBL] [Abstract][Full Text] [Related]
29. In vivo cerebral metabolic and dopaminergic characteristics in multiple system atrophy with orthostatic hypotension.
Xue C; Dou X; Yu C; Zhong Y; Wang J; Zhang X; Xue L; Hu D; Wu S; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):468-480. PubMed ID: 37807003
[TBL] [Abstract][Full Text] [Related]
30. Striatal dopamine transporter availability in unmedicated bipolar disorder.
Anand A; Barkay G; Dzemidzic M; Albrecht D; Karne H; Zheng QH; Hutchins GD; Normandin MD; Yoder KK
Bipolar Disord; 2011 Jun; 13(4):406-13. PubMed ID: 21843280
[TBL] [Abstract][Full Text] [Related]
31. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning.
Zhao Y; Wu P; Wu J; Brendel M; Lu J; Ge J; Tang C; Hong J; Xu Q; Liu F; Sun Y; Ju Z; Lin H; Guan Y; Bassetti C; Schwaiger M; Huang SC; Rominger A; Wang J; Zuo C; Shi K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2798-2811. PubMed ID: 35588012
[TBL] [Abstract][Full Text] [Related]
32. Increased DAT binding in the early stage of the dopaminergic lesion: a longitudinal [11C]PE2I binding study in the MPTP-monkey.
Vezoli J; Dzahini K; Costes N; Wilson CR; Fifel K; Cooper HM; Kennedy H; Procyk E
Neuroimage; 2014 Nov; 102 Pt 2():249-61. PubMed ID: 25108180
[TBL] [Abstract][Full Text] [Related]
33. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
Shi J; Zhao LY; Copersino ML; Fang YX; Chen Y; Tian J; Deng Y; Shuai Y; Jin J; Lu L
Eur J Pharmacol; 2008 Jan; 579(1-3):160-6. PubMed ID: 17977528
[TBL] [Abstract][Full Text] [Related]
34. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of nigrostriatal damage and its change over weeks in a rat model of Parkinson's disease: small animal positron emission tomography studies with [(11)C]beta-CFT.
Liu L; Wang Y; Li B; Jia J; Sun Z; Zhang J; Tian J; Wang X
Nucl Med Biol; 2009 Nov; 36(8):941-7. PubMed ID: 19875050
[TBL] [Abstract][Full Text] [Related]
36. Striatofrontal Deafferentiation in MSA-P: Evaluation with [18F]FDG Brain PET.
Kim HW; Oh M; Oh JS; Oh SJ; Lee SJ; Chung SJ; Kim JS
PLoS One; 2017; 12(1):e0169928. PubMed ID: 28085923
[TBL] [Abstract][Full Text] [Related]
37. Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
Chou KL; Dayalu P; Koeppe RA; Gilman S; Spears CC; Albin RL; Kotagal V
Mov Disord; 2022 Nov; 37(11):2301-2307. PubMed ID: 36102173
[TBL] [Abstract][Full Text] [Related]
38. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism.
Kim JM; Hong S; Kim GP; Choi YJ; Kim YK; Park SS; Kim SE; Jeon BS
Arch Neurol; 2007 Oct; 64(10):1510-8. PubMed ID: 17923635
[TBL] [Abstract][Full Text] [Related]
39. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.
Swanson RL; Newberg AB; Acton PD; Siderowf A; Wintering N; Alavi A; Mozley PD; Plossl K; Udeshi M; Hurtig H
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):302-7. PubMed ID: 15791439
[TBL] [Abstract][Full Text] [Related]
40. Differential alterations of dopamine transporter in the striatum and midbrain in patients with parkinsonian syndrome.
Matesan MC; Cross DJ; Lewis DH; Minoshima S
Clin Nucl Med; 2015 Mar; 40(3):191-4. PubMed ID: 25546191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
